Overexpression of lecithin:retinol acyltransferase in the epithelial basal layer makes mice more sensitive to oral cavity carcinogenesis induced by a carcinogen

Cancer Biology and Therapy

Volumn 8, Issue 13, 2009, Pages 1214-1225

  Tang, Xiao Han ^a   Su, Dan ^a,b   Albert, Martin ^a   Scognamiglio, Theresa ^a   Gudas, Lorraine J ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

4 NQO; Cancer stem cells; Cox 2; Cytokeratin14 (K14); Head and neck squamous cell carcinoma (HNSCC); Keratinocyte; LRAT; Oral cancer; RAR 2; Retinoids; Tongue lesions

Indexed keywords

4 NITROQUINOLINE 1 OXIDE; CYCLOOXYGENASE 2; CYTOKERATIN 14; LECITHIN RETINOL ACYLTRANSFERASE; MESSENGER RNA; RETINOIC ACID RECEPTOR BETA; RETINOIC ACID RECEPTOR BETA2; RETINOL; RETINOL ESTER; UNCLASSIFIED DRUG; ACYLTRANSFERASE; CARCINOGEN; CYCLIN D1; CYCLINE; LECITHIN-RETINOL ACYLTRANSFERASE; PTGS2 PROTEIN, MOUSE; RETINOIC ACID RECEPTOR; RETINOID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHEMICAL CARCINOGENESIS; CONTROLLED STUDY; DISEASE SEVERITY; DYSPLASIA; EPITHELIUM BASAL CELL; FEMALE; GENE OVEREXPRESSION; HYPERPLASIA; MALE; MOUSE; MOUTH CARCINOMA; MOUTH MUCOSA; NONHUMAN; PRECANCER; PROMOTER REGION; SKIN; TONGUE CARCINOMA; TRANSGENE; ANIMAL; CELL TRANSFORMATION; CYTOLOGY; DRUG EFFECT; ENZYMOLOGY; EPITHELIUM CELL; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; MOUTH; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSGENIC MOUSE;

4-NITROQUINOLINE-1-OXIDE; ACYLTRANSFERASES; ANIMALS; CARCINOGENS; CELL TRANSFORMATION, NEOPLASTIC; CYCLIN D1; CYCLOOXYGENASE 2; EPITHELIAL CELLS; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, TRANSGENIC; MOUTH; PROLIFERATING CELL NUCLEAR ANTIGEN; RECEPTORS, RETINOIC ACID; RETINOIDS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 77951887812     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.8.13.8630     Document Type: Article

References (92)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007; 57:43-66.
2. Binnie WH, Rankin KV, Mackenzie IC. Etiology of oral squamous cell carcinoma. J Oral Pathol 1983; 12:11-29.
3. Argiris A, Karamouzis MV, Raben D, Ferris RL. Head and neck cancer. Lancet 2008; 371:1695-709.
4. Brinkman BM, Wong DT. Disease mechanism and biomarkers of oral squamous cell carcinoma. Curr Opin Oncol 2006; 18:228-33.
5. Gudas LJ, Sporn MB, Roberts A. Cellular biology and biochemistry of the retinoids. In: Sporn MB, Roberts, A.B., Goodman, D.S., ed. The Retinoids: Biology, Chemistry, and Medicine. New York: Raven Press, 1994:443-520.
6. Chambon P. A decade of molecular biology of retinoic acid receptors. FASEB J 1996; 10:940-54.
7. Clarke N, Germain P, Altucci L, Gronemeyer H. Retinoids: potential in cancer prevention and therapy. Expert Rev Mol Med 2004; 6:1-23.
8. Hong WK, Itri LM. Retinoids and human cancer. In: Sporn MB, Roberts AB, Goodman DS, eds. The Retinoids: Biology, Chemistry, and Medicine. New York: Raven Press, 1994:597-630.
9. Lotan R. Retinoids in cancer chemoprevention. FASEB J 1996; 10:1031-9.
10. Niles RM. Vitamin A and cancer. Nutrition 2000; 16:573-6.
11. Kawaguchi R, Yu J, Honda J, Hu J, Whitelegge J, Ping P, et al. A membrane receptor for retinol binding protein mediates cellular uptake of vitamin A. Science 2007; 315:820-5.
12. Blaner WS, Olson JA. Retinol and retinoic acid metabolism. In: Sporn MB, Roberts, A.B. and Goodman, D.S., ed. The Retinoids: Biology, Chemistry, and Medicine. New York: Raven Press, 1994:229-56.
13. Ruiz A, Winston A, Lim YH, Gilbert BA, Rando RR, Bok D. Molecular and biochemical characterization of lecithin retinol acyltransferase. J Biol Chem 1999; 274:3834-41.
14. Blaner WS. STRA6, a cell-surface receptor for retinol-binding protein: the plot thickens. Cell Metab 2007; 5:164-6.
15. Liu L, Gudas LJ. Disruption of the lecithin: retinol acyltransferase gene makes mice more susceptible to vitamin a deficiency. J Biol Chem 2005; 280:40226-34.
16. O'Byrne SM, Wongsiriroj N, Libien J, Vogel S, Goldberg IJ, Baehr W, et al. Retinoid absorption and storage is impaired in mice lacking lecithin:retinol acyltransferase (LRAT). J Biol Chem 2005; 280:35647-57.
17. Xue L, Gollapalli DR, Maiti P, Jahng WJ, Rando RR. A palmitoylation switch mechanism in the regulation of the visual cycle. Cell 2004; 117:761-71.
18. Guo X, Gudas LJ. Metabolism of all-trans-retinol in normal human cell strains and squamous cell carcinoma lines from the oral cavity and skin: reduced esterification of retinol in SCC lines. Cancer Res 1998; 58:166-76.
19. Guo X, Knudsen BS, Peehl DM, Ruiz A, Bok D, Rando RR, et al. Retinol metabolism and lecithin:retinol acyltransferase levels are reduced in cultured human prostate cancer cells and tissue specimens. Cancer Res 2002; 62:1654-61.
20. Guo X, Nanus DM, Ruiz A, Rando RR, Bok D, Gudas LJ. Reduced levels of retinyl esters and vitamin A in human renal cancers. Cancer Res 2001; 61:2774-81.
21. Guo X, Ruiz A, Rando RR, Bok D, Gudas LJ. Esterification of all-trans-retinol in normal human epithelial cell strains and carcinoma lines from oral cavity, skin and breast: reduced expression of lecithin:retinol acyltransferase in carcinoma lines. Carcinogenesis 2000; 21:1925-33.
22. Mongan NP, Gudas LJ. Diverse actions of retinoid receptors in cancer prevention and treatment. Differentiation 2007; 75:853-70.
23. Gimenez-Conti IB, Slaga TJ. The hamster cheek pouch model of carcinogenesis and chemoprevention. Adv Exp Med Biol 1992; 320:63-7.
24. Gimenez-Conti IB, Slaga TJ. The hamster cheek pouch carcinogenesis model. J Cell Biochem Suppl 1993; 17F:83-90.
25. Kanojia D, Vaidya MM. 4-nitroquinoline-1-oxide induced experimental oral carcinogenesis. Oral Oncol 2006; 42:655-67.
26. Suzuki R, Kohno H, Suzui M, Yoshimi N, Tsuda H, Wakabayashi K, et al. An animal model for the rapid induction of tongue neoplasms in human c-Ha-ras proto-oncogene transgenic rats by 4-nitroquinoline 1-oxide: its potential use for preclinical chemoprevention studies. Carcinogenesis 2006; 27:619-30.
27. Tanaka T, Kojima T, Okumura A, Yoshimi N, Mori H. Alterations of the nucleolar organizer regions during 4-nitroquinoline 1-oxide-induced tongue carcinogenesis in rats. Carcinogenesis 1991; 12:329-33.
28. Tang XH, Knudsen B, Bemis D, Tickoo S, Gudas LJ. Oral cavity and esophageal carcinogenesis modeled in carcinogen-treated mice. Clin Cancer Res 2004; 10:301-13.
29. Vitale-Cross L, Czerninski R, Amornphimoltham P, Patel V, Molinolo AA, Gutkind JS. Chemical carcinogenesis models for evaluating molecular-targeted prevention and treatment of oral cancer. Cancer Prevention Res 2009; 2(5):419-422.
30. Smith WL, DeWitt DL, Garavito RM. Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 2000; 69:145-82.
31. Cha YI, DuBois RN. NSAIDs and cancer prevention: targets downstream of COX-2. Annu Rev Med 2007; 58:239-52.
32. Chan G, Boyle JO, Yang EK, Zhang F, Sacks PG, Shah JP, et al. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res 1999; 59:991-4.
33. Dannenberg AJ, Lippman SM, Mann JR, Subbaramaiah K, DuBois RN. Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention. J Clin Oncol 2005; 23:254-66.
34. Dubois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, Van De Putte LB, et al. Cyclooxygenase in biology and disease. Faseb J 1998; 12:1063-73.
35. Vishwanatha JK, Swinney R, Banerjee AG. Modulation of annexin I and cyclooxygenase-2 in smokeless tobacco-induced inflammation and oral cancer. Mol Cell Biochem 2003; 248:67-75.
36. Lippman SM, Sudbo J, Hong WK. Oral cancer prevention and the evolution of molecular-targeted drug development. J Clin Oncol 2005; 23:346-56.
37. Nishimura N, Urade M, Hashitani S, Noguchi K, Manno Y, Takaoka K, et al. Increased expression of cyclooxygenase (COX)-2 in DMBA-induced hamster cheek pouch carcinogenesis and chemopreventive effect of a selective COX-2 inhibitor celecoxib. J Oral Pathol Med 2004; 33:614-21.
38. Yoshida K, Tanaka T, Kohno H, Sakata K, Kawamori T, Mori H, et al. A COX-2 inhibitor, nimesulide, inhibits chemically-induced rat tongue carcinogenesis through suppression of cell proliferation activity and COX-2 and iNOS expression. Histol Histopathol 2003; 18:39-48.
39. Chen Z, Zhang X, Li M, Wang Z, Wieand HS, Grandis JR, et al. Simultaneously targeting epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2, an efficient approach to inhibition of squamous cell carcinoma of the head and neck. Clin Cancer Res 2004; 10:5930-9.
40. Lin HY, Sun M, Tang HY, Simone TM, Wu YH, Grandis JR, et al. Resveratrol causes COX-2- and p53-dependent apoptosis in head and neck squamous cell cancer cells. J Cell Biochem 2008; 104:2131-42.
41. Hong WK, Lippman SM, Itri LM, Karp DD, Lee JS, Byers RM, et al. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med 1990; 323:795-801.
42. Lotan R, Xu XC, Lippman SM, Ro JY, Lee JS, Lee JJ, et al. Suppression of retinoic acid receptor-beta in premalignant oral lesions and its up-regulation by isotretinoin. N Engl J Med 1995; 332:1405-10.
43. Hu L, Crowe DL, Rheinwald JG, Chambon P, Gudas LJ. Abnormal expression of retinoic acid receptors and keratin 19 by human oral and epidermal squamous cell carcinoma cell lines. Cancer Res 1991; 51:3972-81.
44. Wan H, Oridate N, Lotan D, Hong WK, Lotan R. Overexpression of retinoic acid receptor β in head and neck squamous cell carcinoma cells increases their sensitivity to retinoid-induced suppression of squamous differentiation by retinoids. Cancer Res 1999; 59:3518-26.
45. Xu XC, Ro JY, Lee JS, Shin DM, Hong WK, Lotan R. Differential expression of nuclear retinoid receptors in normal, premalignant, and malignant head and neck tissues. Cancer Res 1994; 54:3580-7.
46. Moldovan GL, Pfander B, Jentsch S. PCNA, the maestro of the replication fork. Cell 2007; 129:665-79.
47. Sherr CJ. Principles of Tumor Suppression. Cell 2004; 116:235-46.
48. Coleman KG, Wautlet BS, Morrissey D, Mulheron J, Sedman SA, Brinkley P, et al. Identification of CDK4 sequences involved in cyclin D1 and p16 binding. J Biol Chem 1997; 272:18869-74.
49. Morisaki H, Ando A, Nagata Y, Pereira-Smith O, Smith JR, Ikeda K, et al. Complex mechanisms underlying impaired activation of Cdk4 and Cdk2 in replicative senescence: roles of p16, p21, and cyclin D1. Exp Cell Res 1999; 253:503-10.
50. Todd R, Hinds PW, Munger K, Rustgi AK, Opitz OG, Suliman Y, et al. Cell cycle dysregulation in oral cancer. Crit Rev Oral Biol Med 2002; 13:51-61.
51. Hasegawa M, Nelson HH, Peters E, Ringstrom E, Posner M, Kelsey KT. Patterns of gene promoter methylation in squamous cell cancer of the head and neck. Oncogene 2002; 21:4231-6.
52. Hunter KD, Thurlow JK, Fleming J, Drake PJ, Vass JK, Kalna G, et al. Divergent routes to oral cancer. Cancer Res 2006; 66:7405-13.
53. Kresty LA, Mallery SR, Knobloch TJ, Song H, Lloyd M, Casto BC, et al. Alterations of p16(INK4a) and p14(ARF) in patients with severe oral epithelial dysplasia. Cancer Res 2002; 62:5295-300.
54. Papadimitrakopoulou V, Izzo J, Lippman SM, Lee JS, Fan YH, Clayman G, et al. Frequent inactivation of p16INK4a in oral premalignant lesions. Oncogene 1997; 14:1799-803.
55. Sherr CJ. The Pezcoller lecture: cancer cell cycles revisited. Cancer Res 2000; 60:3689-95.
56. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999; 13:1501-12.
57. Sherr CJ. Cell cycle control and cancer. Harvey Lect 2000; 96:73-92.
58. Nakahara Y, Shintani S, Mihara M, Kiyota A, Ueyama Y, Matsumura T. Alterations of Rb, p16(INK4A) and cyclin D1 in the tumorigenesis of oral squamous cell carcinomas. Cancer Lett 2000; 160:3-8.
59. Schoelch ML, Regezi JA, Dekker NP, Ng IO, McMillan A, Ziober BL, et al. Cell cycle proteins and the development of oral squamous cell carcinoma. Oral Oncol 1999; 35:333-42.
60. Yoshida K, Tanaka T, Hirose Y, Yamaguchi F, Kohno H, Toida M, et al. Dietary garcinol inhibits 4-nitroquinoline 1-oxide-induced tongue carcinogenesis in rats. Cancer Lett 2005; 221:29-39.
61. Toker A, Cantley LC. Signalling through the lipid products of phosphoinositide-3-OH kinase. Nature 1997; 387:673-6.
62. Mandal M, Younes M, Swan EA, Jasser SA, Doan D, Yigitbasi O, et al. The Akt inhibitor KP372-1 inhibits proliferation and induces apoptosis and anoikis in squamous cell carcinoma of the head and neck. Oral Oncol 2006; 42:430-9.
63. Alessi DR, Andjelkovic M, Caudwell B, Cron P, Morrice N, Cohen P, et al. Mechanism of activation of protein kinase B by insulin and IGF-1. Embo J 1996; 15:6541-51.
64. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005; 307:1098-101.
65. Jacinto E, Facchinetti V, Liu D, Soto N, Wei S, Jung SY, et al. SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell 2006; 127:125-37.
66. West KA, Brognard J, Clark AS, Linnoila IR, Yang X, Swain SM, et al. Rapid Akt activation by nicotine and a tobacco carcinogen modulates the phenotype of normal human airway epithelial cells. J Clin Invest 2003; 111:81-90.
67. Xu J, Huang H, Pan C, Zhang B, Liu X, Zhang L. Nicotine inhibits apoptosis induced by cisplatin in human oral cancer cells. Int J Oral Maxillofac Surg 2007; 36:739-44.
68. Amornphimoltham P, Sriuranpong V, Patel V, Benavides F, Conti CJ, Sauk J, et al. Persistent activation of the Akt pathway in head and neck squamous cell carcinoma: a potential target for UCN-01. Clin Cancer Res 2004; 10:4029-37.
69. Massarelli E, Liu DD, Lee JJ, El-Naggar AK, Lo Muzio L, Staibano S, et al. Akt activation correlates with adverse outcome in tongue cancer. Cancer 2005; 104:2430-6.
70. Fuchs E. Keratin genes, epidermal differentiation and animal models for the study of human skin diseases. Biochem Soc Trans 1991; 19:1112-5.
71. Fuchs E, Green H. Changes in keratin gene expression during terminal differentiation of the keratinocyte. Cell 1980; 19:1033-42.
72. Tumbar T, Guasch G, Greco V, Blanpain C, Lowry WE, Rendl M, et al. Defining the Epithelial Stem Cell Niche in Skin. Science 2004; 303:359-63.
73. Moise AR, Golczak M, Imanishi Y, Palczewski K. Topology and membrane association of lecithin: retinol acyltransferase. J Biol Chem 2007; 282:2081-90.
74. Ross AC, Zolfaghari R. Regulation of hepatic retinol metabolism: perspectives from studies on vitamin A status. J Nutr 2004; 134:269S-75S.
75. Dalerba P, Cho RW, Clarke MF. Cancer stem cells: models and concepts. Annu Rev Med 2007; 58:267-84.
76. Prince ME, Ailles LE. Cancer stem cells in head and neck squamous cell cancer. J Clin Oncol 2008; 26:2871-5.
77. Prince ME, Sivanandan R, Kaczorowski A, Wolf GT, Kaplan MJ, Dalerba P, et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci U S A 2007; 104:973-8.
78. Fields AL, Soprano DR, Soprano KJ. Retinoids in biological control and cancer. J Cell Biochem 2007; 102:886-98.
79. Matsuura T, Gad MZ, Harrison EH, Ross AC. Lecithin:retinol acyltransferase and retinyl ester hydrolase activities are differentially regulated by retinoids and have distinct distributions between hepatocyte and nonparenchymal cell fractions of rat liver. J Nutr 1997; 127:218-24.
80. Harrison EH, Gad MZ. Hydrolysis of retinyl palmitate by enzymes of rat pancreas and liver. Differentiation of bile salt-dependent and bile salt-independent, neutral retinyl ester hydrolases in rat liver. J Biol Chem 1989; 264:17142-4147.
81. Kurlandsky SB, Duell EA, Kang S, Voorhees JJ, Fisher GJ. Auto-regulation of retinoic acid biosynthesis through regulation of retinol esterification in human keratinocytes. J Biol Chem 1996; 271:15346-52.
82. Linke T, Dawson H, Harrison EH. Isolation and characterization of a microsomal acid retinyl ester hydrolase. J Biol Chem 2005; 280:23287-94.
83. Mestre JR, Subbaramaiah K, Sacks PG, Schantz SP, Tanabe T, Inoue H, et al. Retinoids suppress epidermal growth factor-induced transcription of cyclooxygenase-2 in human oral squamous carcinoma cells. Cancer Res 1997; 57:2890-5.
84. Ren M, Pozzi S, Bistulfi G, Somenzi G, Rossetti S, Sacchi N. Impaired retinoic acid (RA) signal leads to RARbeta2 epigenetic silencing and RA resistance. Mol Cell Biol 2005; 25:10591-603.
85. Arnold I, Watt FM. c-Myc activation in transgenic mouse epidermis results in mobilization of stem cells and differentiation of their progeny. Curr Biol 2001; 11:558-68.
86. Frye M, Gardner C, Li ER, Arnold I, Watt FM. Evidence that Myc activation depletes the epidermal stem cell compartment by modulating adhesive interactions with the local microenvironment. Development 2003; 130:2793-808.
87. Vassar R, Rosenberg M, Ross S, Tyner A, Fuchs E. Tissue-specific and differentiationspecific expression of a human K14 keratin gene in transgenic mice. Proc Natl Acad Sci U S A 1989; 86:1563-7.
88. Nowak JA, Polak L, Pasolli HA, Fuchs E. Hair follicle stem cells are specified and function in early skin morphogenesis. Cell Stem Cell 2008; 3:33-43.
89. Tang XH, Vivero M, Gudas LJ. Overexpression of CRABPI in suprabasal keratinocytes enhances the proliferation of epidermal basal keratinocytes in mouse skin topically treated with all-trans retinoic acid. Exp Cell Res 2008; 314:38-51.
90. Tang XH, Suh MJ, Li R, Gudas LJ. Cell proliferation inhibition and alterations in retinol esterification induced by phytanic acid and docosahexaenoic acid. J Lipid Res 2007; 48:165-76.
91. Gillespie RF, Gudas LJ. Retinoic Acid receptor isotype specificity in f9 teratocarcinoma stem cells results from the differential recruitment of coregulators to retinoic Acid response elements. J Biol Chem 2007; 282:33421-34.
92. Gillespie RF, Gudas LJ. Retinoid regulated association of transcriptional co-regulators and the polycomb group protein SUZ12 with the retinoic acid response elements of Hoxa1, RARbeta(2), and Cyp26A1 in F9 embryonal carcinoma cells. J Mol Biol 2007; 372:298-316.